VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies

Core Viewpoint - Cryoport, Inc. and VGXI, Inc. have formed a strategic partnership to enhance support for biopharmaceutical companies in the development of cell and gene therapies, as well as mRNA-based treatments [1][2][3] Group 1: Partnership Details - The partnership will leverage VGXI's expertise in plasmid DNA manufacturing and Cryoport's supply chain solutions, including biostorage and bioservices from Cryoport's Houston facility [2][3] - Operations for the partnership are set to commence in October 2024, providing comprehensive support for clinical programs [2][3] Group 2: Company Profiles - Cryoport, Inc. is a global leader in supply chain solutions for life sciences, focusing on cell and gene therapies, with over 50 global locations in 17 countries [4][5] - VGXI, Inc. specializes in nucleic acid biopharmaceuticals, including gene therapies and DNA vaccines, with over 20 years of experience in high-quality plasmid DNA production [6] Group 3: Leadership Insights - Jerrell Shelton, CEO of Cryoport, emphasized the partnership's commitment to quality and innovation, aiming to support the development of next-generation therapeutic modalities [3] - Young Park, CEO of VGXI, highlighted the importance of Cryoport as a trusted partner to ensure safe and secure storage and transport of biopharmaceutical assets [3]